|
Novartis drug Afinitor® approved by FDA
|
31 October 2010 |
|
Novartis delivers excellent performance in third quarter
|
22 October 2010 |
|
Aclasta preserves bone mass and provides fracture protection in postmenopausal osteoporosis
|
19 October 2010 |
|
Novartis affirms commitment to sustain efforts toward final elimination of leprosy
|
13 October 2010 |
|
Novartis discontinues development of two investigational compounds
|
06 October 2010 |
|
Novartis sells US rights to the overactive bladder treatment Enablex®
|
28 September 2010 |
|
Novartis gains FDA approval for Gilenya(TM), a novel first-line multiple sclerosis treatment
|
23 September 2010 |
|
Novartis JAK inhibitor provides marked and durable clinical benefits in patients with myelofibrosis
|
16 September 2010 |
|
Meningococcal B vaccine candidate could be first to provide broad coverage against deadly disease
|
13 September 2010 |
|
Novartis and collaborators discover novel antimalarial drug candidate
|
06 September 2010 |